Background
Methods
Statistical analysis
Results
Patient characteristics and treatment
Characteristic | R-CHOP (N = 710) | G-CHOP (N = 704) |
---|---|---|
Median age (range), years | 62.0 (18–83) | 62.0 (18–86) |
Male sex, n (%) | 382 (53.8) | 368 (52.3) |
Geographic region, n (%) | ||
Eastern Europe | 99 (13.9) | 97 (13.8) |
Western Europe | 215 (30.3) | 211 (30.0) |
Central and South America | 19 (2.7) | 13 (1.8) |
North America | 107 (15.1) | 109 (15.5) |
Asia | 256 (36.1) | 258 (36.6) |
Other | 14 (2.0) | 16 (2.3) |
ECOG PS, n (%)a | ||
0–1 | 611 (86.1) | 617 (87.8) |
2 | 99 (13.9) | 86 (12.2) |
Ann Arbor stage, n (%)b | ||
I and II | 171 (24.1) | 169 (24.0) |
III and IV | 538 (75.9) | 535 (76.0) |
IPI risk group, n (%) | ||
Low/low-intermediate | 408 (57.5) | 374 (53.1) |
High-intermediate | 192 (27.0) | 220 (31.3) |
High | 110 (15.5) | 110 (15.6) |
No. of planned CHOP cycles, n (%) | ||
6 | 524 (73.8) | 521 (74.0) |
8 | 186 (26.2) | 183 (26.0) |
LDH elevated, n(%)c | ||
Yes | 403 (57.1) | 415 (59.0) |
Extranodal involvement, n (%) | ||
Yes | 466 (65.6) | 484 (68.8) |
Bulky disease (≥ 7.5 cm), n (%)d | 262 (37.0) | 261 (37.2) |
Median time from diagnosis to randomization (range), dayse | 25.0 (1.0–264.8) | 23.1 (3.0–1104.9) |
Cell of origin, n (%)f | ||
GCB | 269 (58.2) | 271 (57.5) |
ABC | 118 (25.5) | 125 (26.5) |
Unclassified | 75 (16.2) | 75 (15.9) |
Efficacy
Investigator assessment | |||
---|---|---|---|
Endpoint | R-CHOP (N = 710) | G-CHOP (N = 704) | |
Median observation time (range), months | 47.4 (0.1–78.2) | 48.0 (0.1–76.5) | |
Investigator-assessed PFS (primary endpoint) | |||
Patients with event, n (%) | 233 (32.8) | 224 (31.8) | |
5-year PFS, % (95% CI) | 62.6 (58.1–66.8) | 63.8 (59.3–68.0) | |
Stratified HR (95% CI) | 0.94 (0.78–1.12) | ||
P (log-rank)* | P = 0.48 | ||
OS | |||
Patients with event, n (%) | 145 (20.4) | 149 (21.2) | |
5-year OS, % (95% CI) | 77.7 (74.1–80.9) | 77.0 (73.3–80.3) | |
Stratified HR (95% CI) | 1.02 (0.81–1.29) | ||
P (log-rank)* | P = 0.84 | ||
DFS in patients with investigator-assessed CR | |||
Patients with event, n (%) | 78 (19.8) | 93 (22.3) | |
Stratified HR (95% CI)* | 1.19 (0.88–1.61) | ||
Investigator-assessed EFS | |||
Patients with event, n (%) | 265 (37.3) | 257 (36.5) | |
Proportion of EFS at 5 years, % (95% CI) | 58.9 (54.5–63.1) | 60.6 (56.3–64.6) | |
Stratified HR (95% CI) | 0.95 (0.80–1.12) | ||
P (log-rank)* | P = 0.53 | ||
Time to start of new anti-lymphoma treatment | |||
Patients with event, n (%) | 250 (35.2) | 238 (33.8) | |
Stratified HR (95% CI) | 0.93 (0.78–1.12) | ||
P (log-rank)* | P = 0.45 | ||
Investigator-assessed response rate (CT with PET) at end of treatmenta | R-CHOP (N= 665) | G-CHOP (N= 669) | |
ORR | |||
n (%) | 516 (77.6) | 516 (77.1) | |
Percentage difference (95% CI) | − 0.46 (− 5.03–4.11) | ||
CR rate | |||
n (%) | 393 (59.1) | 378 (56.5) | |
Percentage difference (95% CI) | − 2.60 (− 7.97–2.78) | ||
Investigator-assessed response rate (CT without PET) at end of treatmenta | R-CHOP (N= 710) | G-CHOP (N= 704) | |
ORR | |||
n (%) | 569 (80.1) | 573 (81.4) | |
Percentage difference (95% CI) | 1.25 (− 2.93–5.43) | ||
CR rate | |||
n (%) | 241 (33.9) | 249 (35.4) | |
Percentage difference (95% CI) | 1.43 (− 3.61–6.46) |
Safety
Variable | R-CHOP (N = 701) n (%) | G-CHOP (N = 702) n (%) | ||
---|---|---|---|---|
No. of deaths (any reason) | 141 (20.1) | 149 (21.2) | ||
No. of patients withdrawn from the study due to an AE | 4 (0.6) | 6 (0.9) | ||
Patients with ≥ 1 | ||||
AE | 659 (94.0) | 685 (97.6) | ||
Grade 3–5 AE | 461 (65.8) | 527 (75.1) | ||
AE with fatal outcomea | 31 (4.4) | 43 (6.1) | ||
Serious AE | 269 (38.4) | 312 (44.4) | ||
Treatment-related AE | 600 (85.6) | 647 (92.2) | ||
AE leading to withdrawal of any treatment | 58 (8.3) | 8.7 (12.4) | ||
AE leading to dose reduction for any treatment | 142 (20.3) | 145 (20.7) | ||
Grade 3–5 AE, n (%) | Serious AE, n (%) | Grade 3–5 AE, n (%) | Serious AE, n (%) | |
Blood and lymphatic system disorders | ||||
Neutropenia | 277 (39.5) | 38 (5.4) | 336 (47.9) | 54 (7.7) |
Febrile neutropenia | 108 (15.4) | 71 (10.1) | 130 (18.5) | 85 (12.1) |
Leukopenia | 78 (11.1) | – | 104 (14.8) | – |
Anemia | 55 (7.8) | – | 53 (7.5) | – |
Thrombocytopenia | 11 (1.6) | – | 40 (5.7) | – |
Infections and infestations | ||||
Pneumonia | 34 (4.9) | 33 (4.7) | 44 (6.3) | 43 (6.1) |